Introduction {#s1}
============

Chronic obstructive pulmonary disease (COPD) is a complex, heterogeneous disease usually with a decline in lung function and worsening symptoms; hence, both forced expiratory volume in 1 s (FEV~1~; lung function) and validated patient-reported outcomes (PROs) are used in clinical trials to assess disease severity and response to treatment \[[@C1]--[@C4]\]. The PROs are different in terms of their scope of assessment and in the information that they capture. PRO questionnaires such as the Baseline Dyspnoea Index (BDI), Transition Dyspnoea Index (TDI) and modified Medical Research Council (mMRC) dyspnoea scale are used to assess dyspnoea, whereas the Clinical COPD Questionnaire (CCQ), COPD Assessment Test (CAT) and St George\'s Respiratory Questionnaire (SGRQ) are commonly used to assess patients\' health status \[[@C5]--[@C11]\]. Furthermore, the mMRC scale is unidirectional and minimally responsive to treatment interventions, while the BDI, TDI, CAT, CCQ and SGRQ (approved by the USA Food and Drug Administration) are multidirectional \[[@C5]--[@C12]\].

With the availability of numerous PROs, it is important to understand which provide a better evaluation of patients\' health status and demonstrate responses to treatment. Even when PROs evaluate the same parameter, *e.g.* dyspnoea, they may not always capture a uniform response \[[@C13]\]. Hence, it would be useful to examine if the PROs correlate with each other and whether any specific PROs better reflect treatment benefit (as expressed by minimal clinically important differences (MCIDs)) than the others. Furthermore, understanding the relationship between the PROs and lung function (FEV~1~) may provide insights into whether a change in lung function translates to a change perceptible by the patients (assessed through PROs).

The CRYSTAL study assessed a large number of symptomatic, nonfrequently exacerbating COPD patients with moderate airflow limitation, who were directly switched to glycopyrronium or indacaterol/glycopyrronium from prior treatments in a clinical practice setting, with FEV~1~ and TDI evaluated as co-primary end-points \[[@C4]\]. In this *post hoc* analysis, we investigated the associations between the different PROs evaluated in the CRYSTAL trial (mMRC scale, BDI, CAT and CCQ), and between FEV~1~ and the PROs at baseline. We also assessed the associations between clinically relevant changes in PROs and FEV~1~ during the 12-week study period, regardless of the effects of study interventions.

Methods {#s2}
=======

Study design and patients {#s2a}
-------------------------

CRYSTAL was a 12-week, randomised, open-label study in patients with moderate COPD and a history of one exacerbation or less in the previous year ([ClinicalTrials.gov](https://clinicaltrials.gov/) identifier NCT01985334). The study assessed the efficacy and safety of a direct switch from previous treatments to indacaterol/glycopyrronium 110/50 µg or glycopyrronium 50 µg once daily. Patients were categorised based on mMRC grade and prior medication. The detailed study design and patient characteristics have been described in the primary publication of the study \[[@C4]\].

Patients aged ≥40 years were included if they had a clinical diagnosis of moderate COPD, were current or ex-smokers with a smoking history of ≥10 pack-years, mMRC grade ≥1, FEV~1~ ≥50% and \<80% predicted, and FEV~1~/forced vital capacity ratio \<0.70. Patients were excluded if they had a body mass index \>40 kg·m^−2^, history of asthma and more than one COPD exacerbation requiring systemic corticosteroids or antibiotics and/or hospitalisation in the previous 12 months. Baseline treatment included short-acting β~2~-agonists and/or short-acting muscarinic antagonists, or long-acting β~2~-agonists or long-acting muscarinic antagonists, or long-acting β~2~-agonists plus inhaled corticosteroids in free- or fixed-dose combinations.

The CRYSTAL study was conducted in accordance with the guidelines for Good Clinical Practice and as per the ethical principles of the Declaration of Helsinki. The protocol was approved by an independent ethics committee or an institutional review board for each centre in each country (Austria, Belgium, Czech Republic, Denmark, Estonia, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Norway, Poland, Portugal, Romania, Russian Federation, Slovakia, Slovenia, Spain, Sweden and UK). Further details are presented in the primary publication \[[@C4]\].

Assessments {#s2b}
-----------

The present analysis was an exploratory objective of the CRYSTAL study. PROs and FEV~1~ were measured at baseline and at week 12. BDI scores range from 0 to 12 \[[@C5]\], TDI from −9 to +9 \[[@C5]\] and mMRC grades from 0 to 5 \[[@C6]\]. CAT scores range from 0 to 40 \[[@C8]\] and CCQ (and its domain scores: symptoms, functional state and mental state) from 0 to 6 \[[@C7]\]. Lower BDI and TDI scores indicate higher disease burden, whereas higher mMRC, CAT and CCQ scores indicate higher disease burden. FEV~1~ was measured both as absolute volume (mL) and as percentage predicted.

### Baseline correlation analysis {#s2b1}

Relationships among the following PROs were assessed at baseline: 1) mMRC *versus* BDI, CAT and CCQ; 2) BDI *versus* CAT and CCQ; and 3) CAT *versus* CCQ. Correlations between lung function (FEV~1~ % pred) and CAT, BDI and CCQ (total and domain scores) at baseline were also assessed.

### Responder analysis at week 12 {#s2b2}

Patients were defined as responders if they achieved the MCID from baseline of ≥100 mL increase in FEV~1~ \[[@C14]\], ≥1 unit increase in TDI \[[@C5]\], ≥0.4 unit decrease in CCQ \[[@C15]\] or ≥2 unit decrease in CAT \[[@C16]\]. Distribution of responders was assessed based on MCID in PROs only, and in PROs and FEV~1~ together. Although the MCIDs are generally calculated in comparison with placebo, in the CRYSTAL study we have predefined the MCIDs in comparison with the active comparators.

Statistical analysis {#s2c}
--------------------

The intention-to-treat population of the CRYSTAL study, regardless of the study treatment, was used for the analysis. Spearman\'s rank-order analysis was performed to evaluate the relationship between the four PROs, and between FEV~1~ % pred and PROs. The correlation coefficient (r~s~) indicates the strength of correlation. Test for significance was based on the assumption of a correlation coefficient equal to 0.

Results {#s3}
=======

All 4324 patients from the intention-to-treat population of the CRYSTAL study were included in this analysis. Mean age was 64.6 years, with approximately 67% men, 53% current smokers and a moderate airflow limitation (mean post-bronchodilator FEV~1~ 64.7% predicted). Demographics and baseline characteristics are presented in [table 1](#TB1){ref-type="table"}.

###### 

Demographic and baseline characteristics (intention-to-treat population)

  ------------------------------------------------ -------------
  **Patients**                                         4324
  **Age years**                                      64.6±8.30
  **Male**                                          2908 (67.3)
  **Body mass index kg·m^−2^**                       27.6±5.00
  **Current smokers**                               2292 (53.0)
  **Duration of COPD years**                         6.1±5.50
  **mMRC grade**                                   
   1                                                2591 (59.9)
   ≥2                                               1693 (39.2)
  **BDI total score**                                7.3±1.80
  **CAT total score**                                13.2±6.50
  **CCQ total score**                                1.8±0.90
  **Post-bronchodilator FEV~1~ L**                   1.85±0.49
  **Post-bronchodilator FEV~1~ % pred**              64.7±8.70
  **Post-bronchodilator FEV~1~/FVC**                 0.57±0.08
  **Exacerbations in previous 12 months**          
   1                                                867 (20.1)
   ≥2                                                16 (0.4)
  **Baseline treatment**                           
  ** **SABA, SAMA or SABA+SAMA                      496 (11.5)
  ** **LABA+ICS (fixed-dose or free combination)    1059 (24.5)
  ** **LABA (only monotherapy)                      1193 (27.6)
  ** **LAMA (only monotherapy)                      1512 (35.0)
  ** **Others/not applicable/unknown^\#^             187 (4.4)
  ------------------------------------------------ -------------

Data are presented as n, mean±[sd]{.smallcaps} or n (%). COPD: chronic obstructive pulmonary disease; mMRC: modified Medical Research Council dyspnoea scale; BDI: Baseline Dyspnoea Index; CAT: COPD Assessment Test; CCQ: Clinical COPD Questionnaire; FEV~1~: forced expiratory volume in 1 s; FVC: forced vital capacity; SABA: short-acting β~2~-agonist; SAMA: short-acting muscarinic antagonist; LABA: long-acting β~2~-agonist; ICS: inhaled corticosteroid; LAMA: long-acting muscarinic antagonist. ^\#^: LAMA+ICS, LABA+LAMA, ICS monotherapy, LABA+LAMA+ICS (triple), systemic corticosteroids, methylxanthines, roflumilast and others.

Baseline correlation analysis {#s3a}
-----------------------------

At baseline, there was a strong positive correlation between the CAT and CCQ health status questionnaires (r~s~=0.793), while there was a moderate negative correlation between the two dyspnoea questionnaires, *i.e.* BDI and mMRC (r~s~= −0.466). There were moderate negative correlations between BDI and CAT or CCQ (r~s~= −0.437 and −0.451, respectively). In comparison, mMRC showed a weak positive correlation with CAT and CCQ (r~s~=0.356 and 0.380, respectively) ([figure 1](#F1){ref-type="fig"}).

![Plots showing baseline correlation between the modified Medical Research Council (mMRC) dyspnoea scale, Baseline Dyspnoea Index (BDI), COPD Assessment Test (CAT) and Clinical COPD Questionnaire (CCQ). a--c) Box and whisker plots of mMRC *versus* a) BDI, b) CCQ and c) CAT, where BDI, CCQ and CAT have been represented by mMRC grade. Data are presented as median and interquartile range (box) with minimum and maximum values (whiskers). Diamonds indicate mean values and circles indicate outliers. d--f) Scatterplots of d) BDI *versus* CAT, e) BDI *versus* CCQ and f) CAT *versus* CCQ. Spearman\'s rank correlation coefficient (r~s~) values are indicated. COPD: chronic obstructive pulmonary disease.](00243-2018.01){#F1}

At baseline, there was no correlation between lung function (FEV~1~ % pred) and the health status questionnaires (CAT r~s~= −0.068; CCQ r~s~= −0.087) or the dyspnoea questionnaire (BDI r~s~=0.121) ([figure 2](#F2){ref-type="fig"}). Moreover, there was no correlation between lung function and the CCQ domains (symptoms r~s~= −0.070; functional state r~s~= −0.096; mental state r~s~= −0.045).

![Scatterplots showing baseline correlation between forced expiratory volume in 1 s (FEV~1~) % pred and a) COPD Assessment Test (CAT), b) Clinical COPD Questionnaire (CCQ) and c) Baseline Dyspnoea Index (BDI). Spearman\'s rank correlation coefficient (r~s~) values are indicated. COPD: chronic obstructive pulmonary disease.](00243-2018.02){#F2}

Responder analysis {#s3b}
------------------

At week 12, the proportion of patients who were responders was highest for TDI (n=2008 (46.4%)), followed by FEV~1~ (n=1680 (38.9%)), CAT (n=1585 (36.7%)) and CCQ (n=1173 (27.1%)).

Responders to PROs (TDI, CCQ and CAT) {#s3c}
-------------------------------------

Overall, 2774 (64.2%) patients were classified as responders based on MCID in at least one of the three PROs (CAT, TDI and CCQ). Of these, 1365 (31.6%), 826 (19.1%) and 583 (13.5%) patients showed an improvement in one, two or all three PROs, respectively. To evaluate the association between the PROs, the proportions of patients showing a response to combinations of two or more PROs were assessed. Among responders to two PROs, more patients showed an improvement in both CAT and TDI (n=373 (8.6%)) compared with CAT and CCQ (n=271 (6.3%)) and TDI and CCQ (n=182 (4.2%)). In terms of responders to a single PRO, more patients showed an improvement in TDI (n=870 (20.1%)) compared with the other PROs ([figure 3](#F3){ref-type="fig"}).

![Responder analysis based on patient-reported outcomes. COPD: chronic obstructive pulmonary disease; CAT: COPD Assessment Test; TDI: Transition Dyspnoea Index; CCQ: Clinical COPD Questionnaire. Nonresponders n=1550 (35.8%). ^\#^: minimal clinically important difference.](00243-2018.03){#F3}

Responders to FEV~1~, TDI, CCQ and CAT {#s3d}
--------------------------------------

There were 3235 (74.8%) patients found to be responders based on response to FEV~1~ and/or PROs. A higher proportion of patients were responders to PROs alone (n=1555 (36.0%)) compared with a combination of FEV~1~ and one or more PRO responders (n=1219 (28.2%)). Of these, 542 (12.5%), 370 (8.5%) and 307 (7.1%) patients showed an improvement in FEV~1~ and one, two or three PROs, respectively. Among FEV~1~ and two PRO responders, a higher proportion of patients demonstrated a response to a combination of FEV~1~, TDI and CAT (n=186 (4.3%)). Among FEV~1~ and single PRO responders, more patients showed a response to a combination of FEV~1~ and TDI (n=360 (8.3%)) ([figure 4](#F4){ref-type="fig"}).

![Responder analysis based on patient-reported outcomes and forced expiratory volume in 1 s (FEV~1~). COPD: chronic obstructive pulmonary disease. CCQ: Clinical COPD Questionnaire; CAT: COPD Assessment Test; TDI: Transition Dyspnoea Index. Nonresponders n=1089 (25.2%). ^\#^: minimal clinically important difference.](00243-2018.04){#F4}

Responders by subgroup {#s3e}
----------------------

Overall, no differences were observed among the subgroups in responders to PROs, with minor differences between sexes, especially for CCQ. Among FEV~1~ responders, patients aged \<65 years, male and having a bronchodilator reversibility \>12% were more likely to be responders. [Table 2](#TB2){ref-type="table"} shows the descriptive observation of the distribution of patients based on subgroups among responders to PROs and FEV~1~.

###### 

Distribution of responders based on patient-reported outcomes (PROs) and forced expiratory volume in 1 s (FEV~1~) by subgroup

                                             **Patients^\#^**     **TDI**      **CCQ**       **CAT**     **FEV~1~**
  ----------------------------------------- ------------------ ------------- ------------ ------------- -------------
  **Age years**                                                                                         
   \<65                                            2077         993 (47.8)    610 (29.4)   817 (39.3)    874 (42.1)
   ≥65                                             2247         1015 (45.2)   563 (25.1)   768 (34.2)    806 (35.9)
  **Sex**                                                                                               
   Female                                          1416         648 (45.8)    416 (29.4)   531 (37.5)    505 (35.7)
   Male                                            2908         1360 (46.8)   757 (26.0)   1054 (36.2)   1175 (40.4)
  **Smoking status**                                                                                    
   Current smoker                                  2292         1106 (48.3)   664 (29.0)   878 (38.3)    908 (39.6)
   Ex-smoker                                       2028         901 (44.4)    507 (25.0)   705 (34.8)    772 (38.1)
   Never-smoker                                     4            1 (25.0)      2 (50.0)     2 (50.0)       0 (0.0)
  **Exacerbations in previous 12 months**                                                               
   0                                               3441         1602 (46.6)   941 (27.3)   1277 (37.1)   1359 (39.5)
   ≥1                                              883          406 (46.0)    232 (26.3)   308 (34.9)    321 (36.4)
  **Baseline FEV~1~ % pred**                                                                            
   \<60%                                           1367         617 (45.1)    357 (26.1)   476 (34.8)    555 (40.6)
   ≥60%                                            2948         1389 (47.1)   816 (27.7)   1108 (37.6)   1124 (38.1)
  **Bronchodilator reversibility**                                                                      
   ≤12%                                            3251         1521 (46.8)   866 (26.6)   1197 (36.8)   1060 (32.6)
   \>12%                                           1067         486 (45.5)    307 (28.8)   387 (36.3)    619 (58.0)

Data are presented as n or n (%). TDI: Transition Dyspnoea Index; CCQ: Clinical COPD Questionnaire; CAT: COPD Assessment Test. ^\#^: total number of patients; some of the responders showed response to more than one PRO and/or FEV~1~.

Discussion {#s4}
==========

In this analysis of the CRYSTAL study, the PROs CAT and CCQ showed a strong correlation at baseline, while only moderate-to-weak correlations were observed between BDI, CAT, CCQ and mMRC; however, no correlation was observed between lung function (FEV~1~) and any of the PROs at baseline. At week 12, there were small overlaps among the patients who responded to PROs (TDI, CCQ and CAT) and those who responded to FEV~1~ and PROs. Only a very small proportion of patients presented a clinically relevant response to all four parameters studied. These findings are consistent with the outcomes of previous studies that have also been unable to find a substantial correlation between PROs and FEV~1~ \[[@C17], [@C18]\]. This analysis is the first in a large population of patients with moderate airflow limitation involving three different PROs and lung function responses that had already been pre-specified in the study subgroups.

In clinical trials, CAT and CCQ are routinely used to assess patients\' health status and may be considered to be closely related since both assess similar symptoms such as cough and phlegm production. As might be anticipated, these two PROs showed a strong correlation in our statistical analysis, and this is also supported by findings from other *post hoc* studies and meta-analyses \[[@C19]--[@C21]\]. However, while the strong correlation was observed at the group level, some variability was observed at the individual patient level. In contrast, we found that at week 12 only a small proportion of patients presented a clinically relevant response to both of these PROs. This suggests that the cross-sectional evaluation of PROs differs from their longitudinal evaluation and their response to treatment interventions. CCQ includes an additional in-depth evaluation of patients\' physical and mental activities, whereas CAT focuses more on symptoms such as chest tightness and sleep quality \[[@C22]\]. These may lead to greater differences in sensitivity in assessment of treatment response \[[@C4]\], and may account for the differences between findings from the baseline correlation and week 12 responder analysis.

The unidirectional mMRC scale assesses dyspnoea only in terms of the patient\'s level of activity \[[@C6]\], while BDI is multidimensional and assesses functional impairment, the extent of tasks performed and the magnitude of effort expended \[[@C5]\]. This may account for the moderate correlation between BDI and mMRC observed in our analysis. Similar findings were reported in a cross-sectional study in French COPD patients, with the authors suggesting that these PROs are not interchangeable for the evaluation of dyspnoea \[[@C23]\].

In the present analysis, the correlations between the dyspnoea (BDI and mMRC) and health status (CAT and CCQ) PROs were weak at baseline, which was also reflected in the responder analysis at week 12 where there was very little overlap between responders to TDI, CAT and CCQ. These findings are not unexpected as the scope of measurements in the different PROs varies considerably. Furthermore, the relative perception of symptomatic burden in patients receiving the same treatment may be different and thus emphasises the distinct response measured by each PRO \[[@C5], [@C7], [@C8]\].

We did not find any correlations between FEV~1~ and any of the PROs at baseline in this analysis. Furthermore, at week 12, only a small overlap was observed between responders to FEV~1~ and the PROs, despite considerable numbers of patients being responders to PROs alone. Other clinical and retrospective studies also report moderate \[[@C18], [@C24], [@C25]\] to weak or no correlation between FEV~1~ and PROs \[[@C26]--[@C29]\]. FEV~1~ is purely a metric of airflow limitation, while PROs assess the overall wellbeing of patients. Additionally, COPD is a multicomponent disease and not just restricted to airflow limitation, and therefore lung function (FEV~1~) may not accurately reflect disease severity when it is far more complex \[[@C30]\]. This is supported by the revised Global Initiative for Chronic Obstructive Lung Disease strategy, which includes symptoms and exacerbations together with FEV~1~ to assess patients and guide therapy \[[@C31]\]. These responder analysis results clearly show that the PROs used to capture different clinically relevant responses in individual patients are complementary to the improvement of airflow limitation.

Interestingly, FEV~1~ responders demonstrated a greater response based on combinations of PROs that included TDI and CAT compared with those that included CCQ. This is in agreement with a previous pooled analysis of 23 clinical trials of long-acting bronchodilators in patients with COPD of variable severity where D[onohue]{.smallcaps} *et al*. \[[@C32]\] found weak correlations between ΔFEV~1~ and PROs (SGRQ and TDI scores). Although the correlation between FEV~1~ and TDI was weak, these findings suggest the possibility that TDI may more closely reflect the response to treatment in line with improvements in lung function. In our analysis, we found that a greater number of patients responded to TDI alone than the other PROs. This is further supported by the more pronounced improvement in FEV~1~ and TDI in dual bronchodilator-treated patients reported in the primary publication of the CRYSTAL study \[[@C4]\].

Thus, the findings of our analyses reinforce the need to consider both lung function and PROs when evaluating treatment outcomes in patients and guiding COPD management. This was a robust analysis of the CRYSTAL study involving more than 4000 patients, with the PROs and FEV~1~ assessed at the beginning and the end of the trial. Importantly for the interpretation of the results, only nonfrequently exacerbating patients with moderate COPD were included in the analysis; hence, the results may not be applicable to patients with more frequent exacerbations or patients with different disease severities. Furthermore, the study only included assessments up to 12 weeks, which may have an impact on the size of the changes observed in the PROs. Moreover, CRYSTAL was an open-label, non-placebo-controlled study and this may have had some influence on the response to PROs. However, the large number of patients and the fact that our analyses were independent of treatment interventions add value to our results. We have used responder analysis with MCID as a measure of clinically relevant response; however, in all these analyses, we need to consider that MCID values are average estimates obtained in groups of patients and may not identify accurately the perceived benefit of each individual patient \[[@C33]\]. The results of the present analysis suggest that further studies are warranted to evaluate the treatment response of PROs and FEV~1~ in potential composite indexes in other populations of patients with COPD.

Conclusions {#s5}
-----------

Increases in lung function are accompanied by clinically relevant improvements in PROs only in a minority of COPD patients. Our correlation analysis suggests that PROs are not interchangeable; hence, observed treatment success may depend on the parameters selected. Assessments based on both lung function and various PROs may be necessary to obtain a more complete picture of treatment response in patients with COPD and to guide treatment decisions.
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